Dipeptidyl peptidase-4 inhibitors and the ischemic heart: Additional benefits beyond glycemic control.

摘要: Obese-insulin resistance and type 2 diabetes mellitus (T2DM) have become global health problems, they are both associated with a higher risk of ischemic heart disease. Although reperfusion therapy is the treatment to increase blood supply myocardium, this intervention potentially causes cardiac tissue damage instigates arrhythmias, processes known as injury. Dipeptidyl peptidase 4 (DPP-4) inhibitors glycemic control drugs commonly used in T2DM patients. Growing evidence from basic clinical studies demonstrates that DPP-4 inhibitor could exert cardioprotection improve left ventricular function by reducing oxidative stress, apoptosis, increasing injury salvage kinase (RISK) activity. However, recent reports also showed adverse events due use inhibitor. To investigate disparity, future large trials essential verifying whether beneficial beyond their particularly for obese-insulin resistant subjects